## COVID-19 preclinical studies 

We are making our best efforts to collect SARS-CoV-2 in vitro experimental results from recent publications. This dataset will be updated continuously.


|  ﻿Drug Name  | Experimental Activities  | EC50/IC50(μM)  | CC50(μM)  | SI  | 
| ---- | --- | --- | --- | --- | 
|  Remdesivir  | SARS-CoV-2 inhibition  | 0.77  | >100  | >129.87  | 
|  Chloroquine  | SARS-CoV-2 inhibition  | 1.13  | >100  | >88.5  | 
|  Nitazoxanide  | SARS-CoV-2 inhibition  | 2.12  | 35.53  | >16.76  | 
|  Chlorpromazine Hydrochloride  | SARS-CoV-2 inhibition  | 4.03  | 11.88  | 2.94  | 
|  Amodiaquin Dihydrochloride Dihydrate  | SARS-CoV-2 inhibition  | 4.94  | 34.42  | 6.97  | 
|  CVL218  | SARS-CoV-2 inhibition  | 5.12  | 91.05  | 17.78  | 
|  Imatinib Mesylate  | SARS-CoV-2 inhibition  | 5.32  | >30.86  | >5.80  | 
|  Fluspirilene  | SARS-CoV-2 inhibition  | 5.32  | 30.33  | 5.71  | 
|  Amodiaquin Hydrochloride  | SARS-CoV-2 inhibition  | 5.64  | >38.63  | >6.84  | 
|  Triparanol  | SARS-CoV-2 inhibition  | 6.41  | 21.21  | 3.31  | 
|  Clomipramine Hydrochloride  | SARS-CoV-2 inhibition  | 7.59  | >29.68  | >3.91  | 
|  Thiethylperazine Maleate  | SARS-CoV-2 inhibition  | 8.02  | 18.37  | 2.29  | 
|  Mefloquine Hydrochloride  | SARS-CoV-2 inhibition  | 8.06  | 18.53  | 2.3  | 
|  Fluphenazine Dihydrochloride  | SARS-CoV-2 inhibition  | 8.98  | 20.02  | 2.23  | 
|  Tamoxifen Citrate  | SARS-CoV-2 inhibition  | 8.98  | 37.96  | 4.23  | 
|  Promethazine Hydrochloride  | SARS-CoV-2 inhibition  | 10.44  | >42.59  | >4.08  | 
|  Hydroxychloroquine Sulfate  | SARS-CoV-2 inhibition  | 11.17  | >50  | >4.48  | 
|  Toremifene Citrate  | SARS-CoV-2 inhibition  | 11.3  | 20.51  | 1.81  | 
|  Terconazole Vetranal  | SARS-CoV-2 inhibition  | 16.14  | 41.46  | 2.57  | 
|  Benztropine Mesylate  | SARS-CoV-2 inhibition  | 17.79  | >50  | >2.81  | 
|  Nafamostat  | SARS-CoV-2 inhibition  | 22.5  | >100  | >4.44  | 
|  Chloroquine Phosphate  | SARS-CoV-2 inhibition  | 46.8  | >50  | >1.07  | 
|  Favipiravir  | SARS-CoV-2 inhibition  | 61.88  | >400  | >6.46  | 
|  Penciclovir  | SARS-CoV-2 inhibition  | 95.96  | >400  | >4.17  | 
|  Ribavirin  | SARS-CoV-2 inhibition  | 109.5  | >400  | >3.65  | 

[Data Download](https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/COVID19_invitro_assays.csv)

Reference:

1.[Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 2020, 30(3): 269-271.](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)

2.[A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.11.986836v1.abstract)

3.[FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. bioRxiv, 2020.](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)

